Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

View the 50 largest pharmaceutical companies in the world listings here

MERCK

Merck

Rank: 4

Kenilworth, N.J., USA
www.merck.com

2020 Revenues ($USD) : $47,994,000,000
2020 R&D spend : $13,558,000,000
2020 Number of Employees : 74,000
Fiscal Year End : 12/31/2020
Key People : Kenneth C. Frazier, chair and CEO; Robert M. Davis, president, Merck & Co.; Sanat Chattopadhyay, EVP and president, Merck Manufacturing Division; Frank Clyburn, EVP and president, human health; Richard R. DeLuca Jr., EVP and president, Merck animal health; Dr. Julie Louise Gerberding, EVP and chief patient officer, strategic communications, global public policy, & population health; Dr. Dean Y. Li, EVP and president, Merck Research Laboratories; Caroline Litchfield, EVP and CFO; Steven C. Mizell, EVP and chief human resources officer; Dave Williams, chief information & digital officer; Jennifer Zachary, EVP, general counsel and corporate secretary

Merck is developing therapeutic and preventative drugs and vaccines for several conditions. Its development efforts extend to oncology, immunology, neurosciences, virology, cardiovascular, diabetes and women's health. Despite the COVID-19 pandemic, the Kenilworth, N.J.-based pharma giant has made numerous acquisition announcements in the last year to expand its oncology and autoimmune disease treatment portfolios. It acquired Themis for an undisclosed amount in June 2020; OncoImmune for $425 million in November 2020; VelosBio for $2.75 billion in November 2020 and Pandion Therapeutics for $1.85 billion in February 2021. The company has also played a role in the pandemic. It helped J&J produce its COVID-19 vaccine and received funding from BARDA to expand its manufacturing capacity for COVID-19 vaccines and medicines. –DK

Merck

[Automated visual inspection of filled vials. Image courtesy of Merck.]

Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE